The KLOW blend is a research peptide combination that expands on the GLOW formula by adding KPV—a potent anti-inflammatory tripeptide—to the base of GHK-Cu, TB-500, and BPC-157. Packaged in an 80 mg lyophilized vial, KLOW is designed for individuals seeking the comprehensive tissue-repair effects of the GLOW stack with additional support for gut-lining integrity, systemic inflammatory modulation, and immune regulation. This guide explains what KLOW is, what each component contributes, how they synergize, and key practical considerations.

Composition: KLOW contains GHK-Cu 50 mg + TB-500 10 mg + BPC-157 10 mg + KPV 10 mg in a single 80 mg lyophilized vial. The addition of KPV (the tripeptide Lys-Pro-Val) is the defining difference from the GLOW blend.

Fast Answer / Executive Summary

KLOW is a four-peptide blend that combines GHK-Cu (collagen synthesis, genomic repair), TB-500 (systemic cell migration, angiogenesis, anti-fibrotic), BPC-157 (local healing, gut protection, VEGF), and KPV (gut-lining repair, systemic anti-inflammatory, immune regulation) into a single daily subcutaneous injection. KLOW is particularly suited to recovery contexts where gut inflammation, inflammatory bowel conditions, or systemic immune dysregulation accompany musculoskeletal injury.[1][2]

Core Concepts & Key Entities

What is KPV?

KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring neuropeptide with anti-inflammatory and immunomodulatory properties. KPV is the biologically active fragment responsible for much of α-MSH’s anti-inflammatory effect, and it retains this activity at doses far lower than the full-length hormone.[1]

KPV mechanisms in KLOW:

  • Gut-lining repair: KPV penetrates intestinal epithelial cells and directly suppresses NF-κB, reducing pro-inflammatory cytokine output (IL-6, TNF-α) in the gut mucosa.[1]
  • Systemic anti-inflammation: KPV inhibits NF-κB signaling in macrophages and other immune cells, reducing systemic inflammatory burden that can delay tissue healing.[1]
  • Skin barrier protection: Preclinical data show KPV reduces skin inflammation in contact dermatitis and inflammatory skin conditions, complementing GHK-Cu’s dermal effects.
  • MC receptor activation: KPV acts on melanocortin receptors (MC1R, MC3R) which modulate immune and inflammatory responses beyond α-MSH’s endogenous target.

The Three Base Components (GHK-Cu, TB-500, BPC-157)

These operate identically to the GLOW formula:

  • GHK-Cu (50 mg): Copper tripeptide that modulates 4,000+ repair genes, stimulates collagen synthesis, balances MMPs/TIMPs, and reduces inflammation.[2]
  • TB-500 (10 mg): Actin-binding peptide fragment enabling systemic cell migration, angiogenesis, and anti-fibrotic signaling.
  • BPC-157 (10 mg): 15-amino acid peptide driving local repair via FAK-paxillin, VEGF upregulation, and NO-pathway normalization. Also provides direct gut mucosal protection.[3]

Why KLOW over GLOW? When recovery involves significant gut inflammation (e.g., from NSAIDs, antibiotics, IBD flares, or stress-related gut dysfunction), the addition of KPV to the GHK-Cu + TB-500 + BPC-157 foundation provides a meaningful additional layer of mucosal and systemic anti-inflammatory protection. BPC-157 already has gut-protective properties; KPV amplifies and complements this effect through a distinct receptor pathway.

Step-by-Step: How to Work With KLOW

Educational note: KLOW is a research peptide blend not approved for human therapeutic use. This information is educational only and does not constitute medical advice.

Step 1 — Reconstitute the 80 mg vial

Add 4.0 mL bacteriostatic water to the 80 mg KLOW vial → 20.0 mg/mL. At this concentration on a U-100 syringe: 1 unit = 0.01 mL ≈ 200 mcg total blend.

Step 2 — Daily protocol

The standard daily dose is 2,000 mcg (10 units = 0.10 mL) subcutaneously, once daily for a 4-week cycle. At the 4:1:1:1 ratio, each injection delivers approximately:

  • GHK-Cu: ~1,250 mcg
  • TB-500: ~250 mcg
  • BPC-157: ~250 mcg
  • KPV: ~250 mcg

For the full dosing table, reconstitution steps, and supply list, see the KLOW 80 mg Dosage Protocol.

Step 3 — Cycle structure

4 weeks on, 2–4 weeks off. One 80 mg vial provides a 40-day supply at 0.10 mL/day (or a full 28-day cycle with dosing flexibility). A rest period allows assessment of healing progress before deciding on a second cycle.

Step 4 — Injection site

Subcutaneous injection into the abdomen, thigh, or upper arm. Rotate sites daily to prevent local irritation. For injuries with a strong local component, injection near (but not into) the injury site may enhance BPC-157’s local effects.

Comparison & Alternatives

Blend Composition Vial KPV? Best For
Wolverine Stack BPC-157 + TB-500 20 mg No Acute musculoskeletal repair
GLOW GHK-Cu + TB-500 + BPC-157 70 mg No Multi-tissue + skin repair
KLOW GHK-Cu + TB-500 + BPC-157 + KPV 80 mg Yes GLOW + gut/immune inflammatory support

FAQs

1) What is KLOW?
KLOW is an 80 mg research peptide blend containing GHK-Cu, TB-500, BPC-157, and KPV. It builds on the GLOW formula by adding KPV, a tripeptide with potent gut-lining and systemic anti-inflammatory properties, making it well-suited for recovery contexts involving gut or immune involvement alongside tissue injury.

2) What does KPV do?
KPV (Lys-Pro-Val) is the active C-terminal fragment of alpha-MSH that drives anti-inflammatory effects via NF-κB inhibition and melanocortin receptor activation. In the gut, it directly reduces mucosal inflammation; systemically, it modulates macrophage and immune cell inflammatory outputs.[1]

3) How does KLOW differ from GLOW?
KLOW adds KPV to the GLOW stack (GHK-Cu + TB-500 + BPC-157). If your recovery context involves gut inflammation, inflammatory bowel symptoms, systemic immune dysregulation, or skin inflammation, KLOW’s KPV component provides an additional beneficial layer. GLOW remains the choice for pure musculoskeletal and skin recovery without significant gut involvement.

4) What is the KLOW dosage?
The standard research dose is 2,000 mcg (10 units = 0.10 mL) once daily from a 4.0 mL reconstituted 80 mg vial. See the KLOW 80 mg Dosage Protocol for complete details.

5) Is KLOW suitable for IBD or gut conditions?
Preclinical data for both KPV and BPC-157 support gut mucosal repair and anti-inflammatory effects in colitis models. KLOW may be a reasonable research consideration for gut-injury contexts, but human clinical trials have not been conducted. Always consult a qualified healthcare professional for inflammatory bowel conditions.[1][3]

6) Can KLOW help with skin conditions?
The GHK-Cu component has the strongest evidence for skin repair (wound healing, collagen stimulation, post-procedure recovery), while KPV may provide additional support for inflammatory skin conditions. Combined, they represent a compelling research combination for skin health applications.

Evidence Highlights

  • KPV in inflammatory bowel disease (PMC, 2015): KPV significantly reduced colonic inflammation in experimental colitis, reducing TNF-α, IL-6, and NF-κB activity in intestinal tissue. Takeaway: Mechanistic and functional basis for KPV’s gut anti-inflammatory role in KLOW.[1]
  • GHK-Cu gene expression (PMC, 2018): Modulates 4,000+ genes toward repair programs; 31/66 chronic disease genes shifted toward healthy phenotypes. Takeaway: GHK-Cu provides the broadest genomic healing foundation in KLOW.[2]
  • BPC-157 orthopaedic review (PMC, 2025): Extensive preclinical evidence for local musculoskeletal repair across 35 studies. Takeaway: Local healing anchor of the KLOW formula.[3]
  • TB-500 multi-tissue review (Goldstein, 2015): Systemic repair in muscle, tendon, cardiac, cornea, and neural tissue. Takeaway: Systemic reach that distributes KLOW’s benefits body-wide.

Next Steps

Takeaway: KLOW is the most comprehensive research peptide blend for simultaneous tissue repair and inflammatory regulation, making it the preferred option when gut or immune involvement accompanies musculoskeletal or skin injury.